Please login to the form below

Not currently logged in
Email:
Password:

Celsentri launched in the UK

Pfizer's drug Celsentri, the first new oral class of HIV treatment for more than ten years, has been launched in the UK yesterday (November 19).

Pfizer's drug Celsentri (maraviroc), the first new oral class of HIV treatment for more than ten years, has been launched in the UK yesterday (November 19).

Celsentri is now available to treatment experienced patients infected with only CCR5-tropic HIV-1 in combination with other antiretroviral medicinal products in the UK.

Celsentri's is a first in a new class of CCR5 antagonists, and its novel mode of action prevents the HIV virus manufactured infected cells from entering uninfected cells by blocking the CCR5 co-receptor entry route on the cell wall.

Patients will submit to a diagnostic test to verify they have the type of HIV virus treatable with the drug. However, Celsentri could be used for treatment naîve patients and Pfizer is currently studying this possibility in an ongoing study called MERIT.

Celsentri was authorised by the EMEA in September 2007.

A Datamonitor report published in April 2007 projects Celsentri's sales to reach USD 350m in 2015, while the total value of the HIV market could grow to USD 10.6bn in 2015. The HIV market was worth USD 7.1bn in 2005.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics